#101 : A Direct Healthcare Cost Analysis of Recombinant LH Versus hMG Supplementation on FSH During Controlled Ovarian Hyperstimulation in the GnRH-Antagonist Protocol

Abstract

Background and Aims: We have previous proposed a retrospective matched-case control study comparing the effect of recombinant LH versus hMG supplementation on FSH during COH in the GnRH-antagonist protocol. The result showed the cumulative live birth rate (CLBR) was significantly higher the in the LH group (53% vs. 64%, p=0.02). In this study we aim to do the cost analysis between these two groups based on our previous study. Method: The analysis consisted of 425 IVF and ICSI cycles performed in Taichung Veterans General Hospital, Taiwan between 2013 and 2018 in our previous study. They were chosen by Propensity score matching with balanced age, anti-mullerian hormone (AMH) level, and oocyte retrieval date. There were 259 cycles in hMG ± FSH group and 166 cycles in LH ± FSH group. The total cost related to treatment of each patient was recorded. Results: The treatment cost was showed in Table 1. The total treatment cost per patient was significantly higher in the LH than in the hMG group (USD 4194.93 ± 713.6 vs. $ 4466.33 ± 793.18 p=0.001). However, the mean costs per live birth in the hMG goup was higher with US $7875.42, vs. US $6928.83 in the LH group. The analysis of CLBR in the two groups in different treatment cost range results were showed in Figure 1 and Table 2. The CLBR was almost higher in the LH group in each range except for range between USD 5000-5499. When treatment cost between $4000-4499, the CLBR was significantly higher in the LH group than in the hMG group (81.8% vs. 54.3% p=0.006). Conclusions: The cost analysis showed that recombinant LH is more cost effectiveness than hMG supplementation on FSH during COH in the GnRH-antagonist protocol.